Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose –response study and open-label extension study

ConclusionThe UACR-lowering effect of apararenone administered once daily for 24  weeks in patients with stage 2 DN was confirmed, and the 52-week administration was safe and tolerable.Clinical trial registrationNCT02517320 (dose –response study) and NCT02676401 (extension study)
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research